Abstracts tagged "gastrointestinal complications"

Abstract Number: 2898 • 2016 ACR/ARHP Annual Meeting
Anti-Reflux Medications in Diffuse Cutaneous Systemic Sclerosis: Is Empiric Use of Proton Pump Inhibitors Supported?
Tracy M. Frech¹, Ami A. Shah², Monique Hinchcliff³, Flavia V. Castelino⁴, Shervin Assassi⁵, Elana J. Bernstein⁶, Robyn T. Domsic⁷, Jessica K. Gordon⁸, Victoria K. Shanmugam^9,10, Virginia D. Steen¹¹, Maureen Murtaugh¹², Bernie LaSalle¹³, Dinesh Khanna¹⁴ and Faye N. Hant¹⁵, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁶Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology, George Washington University, Great Falls, VA, ¹⁰Division of Rheumatology, The George Washington University, Washington, DC, ¹¹Rheumatology, Georgetown University Medical Center, Washington, DC, ¹²University of Utah, Salt Lake, UT, ¹³University of Utah, Salt Lake City, UT, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Table 1: PRESS
Abstract Number: 2902 • 2016 ACR/ARHP Annual Meeting
Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma– Scleroderma Clinical Trials Consortium Gastrointestinal Working Group
Zsuzsanna McMahan¹, Tracy M. Frech², Guya Piemonte³, Marco Matucci-Cerinic⁴, Susanna Proudman^5,6, Veronica J. Berrocal⁷, Ron Hays⁸ and Dinesh Khanna⁹, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Florence, Florence, Italy, ⁴Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁸UCLA, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 95% of patients with systemic sclerosis (SSc). There is consensus in the Scleroderma Clinical Trials Consortium (SCTC)…
Abstract Number: 2911 • 2016 ACR/ARHP Annual Meeting
A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients
Carolyn Fridley¹ and Virginia D. Steen², ¹Rheumatology, Georgetown University, Washington, DC, ²Rheumatology, Georgetown University Medical Center, Washington, DC
A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease. After skin involvement…
Abstract Number: 827 • 2016 ACR/ARHP Annual Meeting
Severe Gastrointestinal Disease in Early Systemic Sclerosis Is Associated with an Increased Risk of Mortality
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Studies of severe gastrointestinal (GI) disease in systemic sclerosis (SSc) are limited by small, selected samples composed largely of subjects with prevalent disease. We…
Abstract Number: 838 • 2016 ACR/ARHP Annual Meeting
Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Shweta Kishore¹, Santhanam Lakshminarayanan¹, Chia-Ling Kuo² and Ranadeep Mandhadi¹, ¹Division of Rheumatology, University of Connecticut, Farmington, CT, ²Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease with pulmonary involvement seen in 75% of patients and esophageal involvement in 90% of the patients.…
Abstract Number: 839 • 2016 ACR/ARHP Annual Meeting
Immunosuppression Does Not Prevent Severe Gastrointestinal Disease in Systemic Sclerosis
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Severe gastrointestinal (GI) disease is associated with considerable morbidity and high mortality in systemic sclerosis (SSc). There are no known preventative treatments. We wished…
Abstract Number: 974 • 2016 ACR/ARHP Annual Meeting
Diffuse Scleroderma, Male Sex, and Myopathy Are Associated with Severe Gastrointestinal Dysmotility in Scleroderma
Zsuzsanna McMahan¹, Livia Casciola-Rosen² and Fredrick M. Wigley³, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Despite the fact that up to 90% of scleroderma (SSc) patients are affected by gastrointestinal (GI) dysmotility, features associated with severe GI disease are…
Abstract Number: 1853 • 2016 ACR/ARHP Annual Meeting
Klf5+/-;Fli1+/- Mice Recapitulate Protracted Wound Healing and Cardiac and Intestinal Involvement Associated with Systemic Sclerosis
Kouki Nakamura¹, Yoshihide Asano², Takuya Miyagawa³, Megumi Hirabayashi³, Takashi Yamashita³, Ryosuke Saigusa¹, Shunsuke Miura², Tetsuo Toyama^3,4, Takehiro Takahashi¹, Yohei Ichimura¹, Takashi Taniguchi¹, Ayumi Yoshizaki³, Maria Trojanowska⁴ and Shinichi Sato¹, ¹Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁴Arthritis Center, Boston University, Arthritis Center, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by vasculopathy and tissue fibrosis. Although the most recognizable manifestation is skin disease, SSc can…
Abstract Number: 829 • 2015 ACR/ARHP Annual Meeting
Fecal Incontinence and Association with Bowel Dysfunction in Systemic Sclerosis: A Canadian Multicenter Study
Nicolas Richard^1,2, Marie Hudson², Genevieve Gyger², Murray Baron³, Evelyn Sutton⁴, Nader A. Khalidi⁵, Janet E. Pope⁶, Nathalie Carrier¹, Maggie J. Larche⁵, Alexandra Albert⁷, Paul R. Fortin⁷, Carter Thorne⁸, Ariel Masetto⁹ and Canadian Scleroderma Research Group, ¹Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ²McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁴Rheumatology, Dalhousie University, Nova Scotia Rehabilitation Centre, Halifax, NS, Canada, ⁵McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁶Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ⁷Université Laval, CHU de Québec, Québec, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Gastrointestinal (GI) tract involvement is a common and serious complication of systemic sclerosis (SSc). However, the prevalence of fecal incontinence (FI) and its relationship…
Abstract Number: 831 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Decreases the Frequency of Endoscopic Therapy for Gastric Antral Vascular Ectasia in Patients with Systemic Sclerosis
Tiffany Lin¹, James Bena², Shannon Morrison² and Soumya Chatterjee³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Gastric antral vascular ectasia (GAVE) is an increasingly recognized cause of upper gastrointestinal bleeding in patients with systemic sclerosis (SSc). These patients may require…
Abstract Number: 940 • 2015 ACR/ARHP Annual Meeting
NOD2-Associated Autoinflammatory Disease: Therapy and Outcomes
Qingping Yao¹ and Bo Shen², ¹Cleveland Clinic, Cleveland, OH, ²Gastroenterology, Cleveland Clinic, Cleveland, OH
Background/Purpose: NOD2-associated autoinflammatory disease, now redesignated as Yao Syndrome(YS) is a newly described and increasingly recognized entity. It is characterized by periodic fever, dermatitis, polyarthritis, sicca-like…
Abstract Number: 2978 • 2015 ACR/ARHP Annual Meeting
Longitudinal Assessment of Gastrointestinal Symptoms in the Prospective Registry of Early Systemic Sclerosis Cohort
Tracy M. Frech¹, Maureen Murtaugh², Jessica K. Gordon³, Robyn T. Domsic⁴, Ami A. Shah⁵, Faye N. Hant⁶, Shervin Assassi⁷, Monique E. Hinchcliff⁸, Elana J. Bernstein⁹, Virginia D. Steen¹⁰, Victoria K. Shanmugam^11,12 and Dinesh Khanna¹³, ¹Div of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake, UT, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁸Division of Rheumatology, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁹Columbia University, New Yory, NY, ¹⁰Rheumatology, Georgetown University Medical Center, Washington, DC, ¹¹Director, Division of Rheumatology, The George Washington University, Washington, DC, ¹²Division of Rheumatology, The George Washington University, Washington, DC, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) is a multicenter incident cohort study of patients with early diffuse cutaneous systemic sclerosis (dcSSc; <…
Abstract Number: 2979 • 2015 ACR/ARHP Annual Meeting
Laser Speckled Imaging and Videomicroscopy Assessment of Sublingual Perfusion in Systemic Sclerosis and Healthy Controls
Mark Sievert¹, Daniel R. Machin², Anthony J. Donato², Maureen Murtaugh³, John D. Pauling⁴, Robyn T. Domsic⁵, Lee S. Shapiro⁶ and Tracy M. Frech⁷, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake, UT, ³University of Utah, Salt Lake, UT, ⁴Upper Borough Walls, Royal National Hospital for Rheumatic Disease, Bath, United Kingdom, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Steffens Scleroderma Center, Albany, NY, ⁷Div of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Our group has previously described the sublingual frenulum abnormalities in systemic sclerosis (SSc, scleroderma). The goal of this project was to assess microvascular abnormalities…
Abstract Number: 3129 • 2015 ACR/ARHP Annual Meeting
Integrative Analysis of the Colonic Microbiota in Systemic Sclerosis
Elizabeth R. Volkmann¹, Yu-Ling Chang², Nashla Barroso³, Daniel E. Furst³, Philip J. Clements¹, Alan Gorn⁴, Bennett Roth³, Jeffrey Conklin³, Terri Getzug³, Maomeng Tong², Jonathan Jacobs³ and Jonathan Braun², ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Pathology and Laboratory Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: Gastrointestinal tract (GIT) dysfunction is a leading cause of morbidity in patients with systemic sclerosis (SSc). However, the etiology of SSc-related lower GIT dysfunction…
Abstract Number: 3136 • 2015 ACR/ARHP Annual Meeting
Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review
Annaliese Tisseverasinghe¹, Ahmad Kadhim², Ambica Parmar², Louis Liu² and Sindhu R. Johnson¹, ¹Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Division of Gastroenterology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: More than 90% of patients with Systemic Sclerosis (SSc) have gastroinstestinal (GI) involvement, commonly dysmotility causing complications such as gastroesophageal reflux and constipation. Treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].